via The Scientist RSS https://ift.tt/EAWYKNx bit.bio’s new ioGlutamatergic Neurons HTT50CAG/WT provide a human, cell-based, in vitro model of Huntington’s Disease (HD) that accurately reflects the disease genotype. Offering industry-leading consistency and scalability, this first product from the new ioDisease Model portfolio has been developed to support key applications within drug discovery including target identification and high-throughput screening. https://ift.tt/aZhUgyR June 10, 2022 at 12:16AM